Maria Ignez Braghiroli, MD, discusses a study that parsed out patients with solely NRAS-mutated colorectal cancer, what the current treatment paradigm is for these patients, and how the mutation status of a patient with colorectal cancer may affect their treatment.
The combination of PEGPH20 with nab-paclitaxel and gemcitabine demonstrated improvements in progression-free survival compared with nab-paclitaxel/gemcitabine alone for untreated patients with advanced pancreatic cancer.
Tanios Bekaii-Saab, MD, discusses questions regarding regorafenib and TAS-102 in mCRC, compares the mechanisms of action and toxicities of both therapies, and shares his views on the optimal sequencing of the 2 agents.
Multidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival (OS) for patients with early-stage hepatocellular carcinoma.
Alan P. Venook, MD, discusses several of the big queries that remain in mCRC and the possible explanations for survival differences between left- and right-sided tumors. He also explained how answering these questions could pave the way for more novel treatment approaches.
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) for previously treated patients with advanced microsatellite instability-high (MSI-H) cancer.
Tim F. Greten, MD, senior investigator, Thoracic and Gastrointestinal Oncology Branch, and head, Gastrointestinal Malignancy Section, National Cancer Institute Center for Cancer Research, discusses the possibility for immunotherapy in liver cancer.
Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Practitioners received insight into treating patients across the GI field during the GI cancers track at the 2016 Chemotherapy Foundation Symposium.
Howard S. Hochster, MD, professor of Medical Oncology, and Yale Cancer Center Associate Director (for Clinical Sciences), discusses steps that can be taken to tackle some of the challenges that remain in the field of pancreatic cancer.
Early evidence suggests that the combination of locoregional therapy with an immune checkpoint inhibitor is a safe and effective strategy to pursue for patients with advanced hepatocellular carcinoma (HCC), according to a leading liver immunology expert.
Dafna Bar-Sagi, PhD, vice dean for science and chief scientific officer of NYU Langone Medical Center, and a senior member of its Perlmutter Cancer Center, was recently named a recipient of the Outstanding Investigator Award from the National Cancer Institute (NCI).
Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses how mutation status effects individualization of treatment in metastatic colorectal cancer (mCRC).
Charles S. Fuchs, MD, MPH, has been appointed the new director and physician-in-chief of Smilow Cancer Hospital at Yale Cancer Center (YCC) in New Haven, Connecticut.
In patients with metastatic colorectal cancer (mCRC), the correlation between tumor location and improved survival varies based on stage of disease, according to a study.
Pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil (5-FU) and leucovorin has been approved by the European Commission (EC) for patients with metastatic pancreatic adenocarcinoma.
Mutation discordance between primary and metastatic sites in colorectal cancer (CRC) may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.
A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.
A genetic understanding of dMMR in rectal cancer could lead the way to precision medicine for these subgroups of patients
James Hsieh, MD, PhD, discusses the 3 "eras" in the treatment of kidney cancer.
Michael Choti, MD, discusses the importance of biomarkers when it comes to choosing treatments, which treatments to choose for certain patients with GI cancer, and the improvement of systemic therapy.
Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the need for better surrogate parameters for overall survival in colorectal cancer.
As gastric cancers continue to be classified into different subtypes, oncologists will now have the opportunity to improve treatment by determining which targeted agents are appropriate for which subtypes, said Howard S. Hochster, MD.<br />
Metastatic Pancreatic Cancer With George P. Kim, MD, and Eileen M. O'Reilly, MD
